MAM14 Immunotherapy New Modality Treat Autoimmune Disorder

Abstract

There is no safe single treatment for autoimmune disorders until this writing. This new modality is challenging this notion with safe no toxic method named MAM14 immunotherapy. This new method have been tried on several types of autoimmune disorders in the last 25 years in our lab at Kuwait University Faculty of Medicine. In this article we demonstrate the difference of MAM14 on four out of the 14 autoimmune disorder studied compared to control who received conventional chemotherapy.  Data accumulated of 1400 patients compared to 1400 controls. For the present article the sample we chose 10 patients treated with MAM14 for each disease studied compared to 10 control- patients from the same sickness but treated by conventional immunosuppressant chemotherapy, Cyclosporine, Methotrexate ,Tacrolimus or steroid.  MAM14 immunotherapy In brief is vaccination of patients by allogeneic stressed peripheral blood lymphocytes.   Peripheral Blood Lymphocytes isolated from venous whole blood on Ficoll-Paque centrifugation.Cultured for 24 hours in sterile physiological enriched media. Vaccinated subcutaneously into forearm of patients. Vaccination given every 4 weeks for four visits.  4 autoimmune disorder included in this study namely insulin dependent diabetes mellitus, rheumatoid arthritis, multiple sclerosis and anterior uveitis. Total 40 patients-  treated by MAM14 method 10 patients of each disease compared to 10 control patients of the same disorder but on conventional chemotherapy. Prism Graph pad biostatistical package was used for data analysis.  Data accumulated showed significant improvement in signs and symptoms of the present autoimmune disorders studied. Namely insulin dependent diabetes mellitus, rheumatoid arthritis, multiple sclerosis and anterior uveitis.  MAM14 immunotherapy showed superior improvement and safety on the long run compared to control patients who receive conventional immunosuppressant.Mechanism postulated that culturing cells in vitro cause shedding of antigens, these antigens direct autoreactive pathogenic T cells convert to regulatory protective T cells in the presence of peripheral stem cells leading to restoring tolerance and switching off autoimmunity reaction.